It has been reported that trifluoperazine effectively inhibited cisplatin-resistant metastatic bladder urothelial carcinoma and circumvented cisplatin resistance with concurrent Bcl-xL downregulation [66]. Here, BCL2L1 is linked to bladder transitional cell carcinoma.